Kendall Capital Management’s Quest Diagnostics DGX Stock Holding History

Kendall Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,570	Closed	-$313K	–	205
2023 Q3	$313K	Sell	2,570 -1,235	-32%	-$165K	0.14%	154
2023 Q2	$535K	Sell	3,805 -1,300	-25%	-$179K	0.23%	119
2023 Q1	$722K	Sell	5,105 -75	-1%	-$10.7K	0.35%	100
2022 Q4	$810K	Sell	5,180 -255	-5%	-$36.6K	0.41%	83
2022 Q3	$667K	Sell	5,435 -120	-2%	-$15.8K	0.39%	84
2022 Q2	$739K	Sell	5,555 -270	-5%	-$36.8K	0.41%	79
2022 Q1	$797K	Sell	5,825 -120	-2%	-$16.7K	0.39%	83
2021 Q4	$1.03M	Buy	5,945 +110	+2%	+$16.7K	0.49%	69
2021 Q3	$848K	Buy	5,835 +1,790	+44%	+$262K	0.46%	75
2021 Q2	$534K	Buy	+4,045	New	+$530K	0.3%	94

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Kendall Capital Management's DGX Position: Q4 2023 in Review

Kendall Capital Management sold out of Quest Diagnostics (DGX) in Q4 2023, closing a stake of 2,570 shares — an estimated $313K sold.

Kendall Capital Management first reported a position in DGX in Q2 2021 and held it in 10 quarters. The position peaked at $1.03M in Q4 2021. 827 funds tracked by Wall St. Rank hold DGX as of Q4 2023.

Kendall Capital Management reported no remaining Quest Diagnostics position as of Q4 2023 after selling out during the quarter.
Kendall Capital Management sold 2,570 Quest Diagnostics shares in Q4 2023, an estimated $313K.
Kendall Capital Management first reported a position in Quest Diagnostics in Q2 2021 and held it in 10 quarters.
Kendall Capital Management's Quest Diagnostics position peaked at $1.03M in Q4 2021.
827 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2023.

Based on Kendall Capital Management's 13F filing for Q4 2023, filed 26 Jan 2024.